— Abstract accepted for late-breaking poster presentation – — EO-1022 is a potentially differentiated HER3 ADC being developed for the treatment of solid tumors, including breast and non-small cell lung cancers — — On-track to file an Investigational New Drug (IND) application in 2026…

Preclinical data reinforce therapeutic potential of ATX-559, a first-in-class oral DHX9 inhibitor, in cancers characterized by genomic instability and replication stress Novel KIF18A inhibitor, ATX-295, selected for oral presentation discussing robust, selective activity in ovarian cancer…

Data to be presented from the STARt-001 trial demonstrating single agent anti-tumor activity CAMBRIDGE, Mass., March 25, 2025 /PRNewswire/ — Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology and…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.